Philip Hardy, MD
Family Medicine · Orlando, FLNPI 1548247869
Payments from drug & device makers
Across 457 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- AstraZeneca$996
- Boehringer Ingelheim$754
- GSK$447
- AbbVie$413
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$130%
- Food & beverage$7,55299%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 72 | $1,229 |
| Lilly USA, LLC | 65 | $1,120 |
| AstraZeneca | 53 | $996 |
| Boehringer Ingelheim | 67 | $754 |
| GSK | 29 | $447 |
| AbbVie(2 entities) | 27 | $413 |
| Amgen | 21 | $302 |
| Eisai Inc. | 11 | $185 |
| Astellas Pharma US Inc | 7 | $171 |
| Merck | 10 | $171 |
| Johnson & Johnson(3 entities) | 7 | $158 |
| Bayer | 8 | $154 |
| Amarin Pharma, Inc. | 7 | $140 |
| Idorsia Pharmaceuticals US Inc | 9 | $136 |
| Abbott | 7 | $131 |
| Exact Sciences | 5 | $130 |
| Pfizer | 3 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $98 |
| Phadia US Inc. | 4 | $89 |
| Teva Pharmaceuticals USA, Inc. | 4 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $66 |
| Bausch Health US, LLC | 3 | $65 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $65 |
| Daiichi Sankyo Inc. | 4 | $61 |
| Endo Pharmaceuticals Inc. | 3 | $44 |
| Renalytix AI, Inc. | 2 | $43 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Novartis | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Medicure Pharma Inc. | 2 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Medtronic | 1 | $23 |
| Lucid Diagnostics Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $15 |
How this compares
$7,636 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 60 | $76,056 |
| TrulicityDulaglutide | 26 | $53,592 |
| MounjaroTirzepatide | 21 | $45,091 |
| OzempicSemaglutide | 25 | $32,777 |
| FarxigaDapagliflozin Propanediol | 14 | $18,802 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $16,988 |
| MyrbetriqMirabegron | 16 | $14,670 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $14,383 |
| EliquisApixaban | 14 | $10,642 |
| LivaloPitavastatin Calcium | 20 | $8,426 |
| Rosuvastatin Calcium | 358 | $5,226 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 26 | $3,451 |
| SynthroidLevothyroxine Sodium | 25 | $2,110 |
| Levothyroxine Sodium | 146 | $1,869 |
| Gabapentin | 54 | $1,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,120 | $98,68347 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $754 | $90,43973 claims |
| Novo NordiskOzempic | $1,229 | $32,77725 claims |
| AstraZenecaFarxiga | $996 | $18,80214 claims |
| GSKTrelegy Ellipta | $447 | $16,98814 claims |
| Astellas Pharma US IncMyrbetriq | $171 | $14,67016 claims |
| PfizerEliquis | $103 | $10,64214 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $29 | $8,42620 claims |
| AbbVieSynthroid | $413 | $2,11025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Orlando
- Eva-Maria HeurichOrlando$11.3M
- Humberto CruzOrlando$10.7M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.